Literature DB >> 21284527

Vascular endothelial growth factors in retinal and choroidal neovascular diseases.

Kati Kinnunen1, Seppo Ylä-Herttuala.   

Abstract

Angiogenesis, or neovascularization, refers to development of new vessels from pre-existing vasculature. Retinal and choroidal neovascularization leads to oedema, haemorrhages, and fibrosis, causing visual impairment and blindness. In multiple studies, vascular endothelial growth factor (VEGF) has been shown to be the most important factor in ocular angiogenesis. Recently discovered anti-VEGF treatments have revolutionized the therapy of neovascular diseases in the eye. These agents have been shown not just to stop the angiogenic process and maintain visual acuity but also improve vision in a great proportion of patients at least during a 2-year follow-up. However, there are also problems with these agents and their delivery regimens, and new therapeutic strategies are needed. This review summarizes the most important growth factors participating in the angiogenic process in the retina and the choroid, diseases where angiogenesis plays the most devastating part causing visual impairment, as well as current antiangiogenic treatments for these diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284527     DOI: 10.3109/07853890.2010.532150

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  19 in total

Review 1.  Notch signaling in ocular vasculature development and diseases.

Authors:  Guo-Rui Dou; Lin Wang; Yu-Sheng Wang; Hua Han
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 2.  Animal models of ocular angiogenesis: from development to pathologies.

Authors:  Chi-Hsiu Liu; Zhongxiao Wang; Ye Sun; Jing Chen
Journal:  FASEB J       Date:  2017-07-24       Impact factor: 5.191

Review 3.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

4.  Risk of choroidal neovascularization among the uveitides.

Authors:  Sally L Baxter; Maxwell Pistilli; Siddharth S Pujari; Teresa L Liesegang; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; John H Kempen
Journal:  Am J Ophthalmol       Date:  2013-06-21       Impact factor: 5.258

5.  Molecular responses of choroidal endothelial cells to elastin derived peptides through the elastin-binding protein (GLB1).

Authors:  Jessica M Skeie; Jasmine Hernandez; Aleksander Hinek; Robert F Mullins
Journal:  Matrix Biol       Date:  2011-12-02       Impact factor: 11.583

6.  Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization.

Authors:  Zhongxiao Wang; Rui Cheng; Kyungwon Lee; Puneet Tyagi; Lexi Ding; Uday B Kompella; Jing Chen; Xun Xu; Jian-Xing Ma
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-05       Impact factor: 8.311

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

8.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-12-04       Impact factor: 3.534

9.  Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.

Authors:  Qiao-Ying You; Fu-Yuan Zhuge; Qi-Qian Zhu; Xu-Wei Si
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

10.  Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.

Authors:  Britta M Rauck; Thomas R Friberg; Carlos A Medina Mendez; Daewon Park; Veeral Shah; Richard A Bilonick; Yadong Wang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-23       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.